Advertisement

Journal of General Internal Medicine

, Volume 27, Issue 12, pp 1594–1601 | Cite as

Impact of Lifestyle Intervention and Metformin on Health-Related Quality of Life: the Diabetes Prevention Program Randomized Trial

  • Hermes FlorezEmail author
  • Qing Pan
  • Ronald T. Ackermann
  • David G. Marrero
  • Elizabeth Barrett-Connor
  • Linda Delahanty
  • Andrea Kriska
  • Christopher D. Saudek
  • Ronald B. Goldberg
  • Richard R. Rubin
  • for the Diabetes Prevention Program Research Group
Original Research

ABSTRACT

BACKGROUND

Adults at high risk for diabetes may have reduced health-related quality of life (HRQoL).

OBJECTIVE

To assess changes in HRQoL after interventions aimed at diabetes risk reduction.

DESIGN, SETTING, AND PARTICIPANTS

A randomized clinical trial, the Diabetes Prevention Program, was conducted in 27 centers in the United States, in 3,234 non-diabetic persons with elevated fasting and post-load plasma glucose, mean age 51 years, mean BMI 34 Kg/m²; 68 % women, and 45 % members of minority groups.

INTERVENTIONS

Intensive lifestyle (ILS) program with the goals of at least 7 % weight loss and 150 min of physical activity per week, metformin (MET) 850 mg twice daily, or placebo (PLB).

MEASUREMENTS

HRQoL using the 36-Item Short-Form (SF-36) health survey to evaluate health utility index (SF-6D), physical component summaries (PCS) and mental component summaries (MCS). A minimally important difference (MID) was met when the mean of HRQoL scores between groups differed by at least 3 %.

RESULTS

After a mean follow-up of 3.2 years, there were significant improvements in the SF-6D (+0.008, p = 0.04) and PCS (+1.57, p < 0.0001) scores in ILS but not in MET participants (+0.002 and +0.15, respectively, p = 0.6) compared to the PLB group. ILS participants showed improvements in general health (+3.2, p < 0.001), physical function (+3.6, p < 0.001), bodily pain (+1.9, p = 0.01), and vitality (+2.1, p = 0.01) domain scores. Treatment effects remained significant after adjusting sequentially for baseline demographic factors, and for medical and psychological comorbidities. Increased physical activity and weight reduction mediated these ILS treatment effects. Participants who experienced weight gain had significant worsening on the same HRQoL specific domains when compared to those that had treatment-related (ILS or MET) weight loss. No benefits with ILS or MET were observed in the MCS score.

CONCLUSION

Overweight/obese adults at high risk for diabetes show small improvement in most physical HRQoL and vitality scores through the weight loss and increased physical activity achieved with an ILS intervention.

KEY WORDS

quality of life lifestyle metformin diabetes risk weight loss 

Notes

Acknowledgements

The Investigators gratefully acknowledge the commitment and dedication of the participants of the DPP. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical centers and the Coordinating Center for the design and conduct of the study; and collection, management, analysis, and interpretation of the data. The Southwestern American Indian Centers were supported directly by the NIDDK and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources, supported data collection at many of the clinical centers. Funding for data collection and participant support was also provided by the Office of Research on Minority Health, the National Institute of Child Health and Human Development, the National Institute on Aging, the Centers for Disease Control and Prevention, the Office of Research on Women’s Health, and the American Diabetes Association. Bristol-Myers Squibb and Parke-Davis provided medication. This research was also supported, in part by the intramural research program of the NIDDK. LifeScan Inc., Health O Meter, Hoechst Marion Roussel, Inc., Merck-Medco Managed Care, Inc., Merck and Co., Nike Sports Marketing, Slim Fast Foods Co., and Quaker Oats Co. donated materials, equipment, or medicines for concomitant conditions. McKesson BioServices Corp., Matthews Media Group, Inc., and the Henry M. Jackson Foundation provided support services under subcontract with the Coordinating Center. The opinions expressed are those of the investigators and do not necessarily reflect the views of the Indian Health Service or other funding agencies. A complete list of Centers, investigators, and staff can be found in the online appendix.

The work was also supported in part by the VA-GRECC/ University of Miami CTSI program and HHS/NIH grant 1R18AE000049-01[HF].

Conflict of Interest

The authors declare that they do not have a conflict of interest related to this manuscript.

Supplementary material

11606_2012_2122_MOESM1_ESM.doc (182 kb)
ESM 1 (DOC 182 kb)

REFERENCES

  1. 1.
    US Department of Health and Human Services (DHSS). In: Healthy people 2020. Washington; 2010. Available at http://healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicId=8 Accessed May 18, 2012.
  2. 2.
    Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life: a population study. Diabetes Care. 2004;27(5):1066–1070.PubMedCrossRefGoogle Scholar
  3. 3.
    Manuel DG, Schultz SE. Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996–1997. Diabetes Care. 2004;27(2):407–414.PubMedCrossRefGoogle Scholar
  4. 4.
    U.K. Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22(7):1125–1136.CrossRefGoogle Scholar
  5. 5.
    Redekop WK, Koopmanschap MA, Rutten GE, Wolffenbuttel BH, Stolk RP, Niessen LW. Resource consumption and costs in Dutch patients with type 2 diabetes mellitus. Results from 29 general practices. Diabet Med. 2002;19(3):246–253.PubMedCrossRefGoogle Scholar
  6. 6.
    Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health. 2001;4(5):392–400.PubMedCrossRefGoogle Scholar
  7. 7.
    Tapp RJ, Dunstan DW, Phillips P, Tonkin A, Zimmet PZ, Shaw JE, AusDiab Study Group. Association between impaired glucose metabolism and quality of life: results from the Australian diabetes obesity and lifestyle study. Diabetes Res Clin Pract. 2006;74(2):154–161.PubMedCrossRefGoogle Scholar
  8. 8.
    Taylor LM, Spence JC, Raine K, Plotnikoff RC, Vallance JK, Sharma AM. Physical activity and health-related quality of life in individuals with prediabetes. Diabetes Res Clin Pract. 2010;90(1):15–21.PubMedCrossRefGoogle Scholar
  9. 9.
    Knowler WC, Barrett-Connor E, Fowler SE, Diabetes Prevention Program Research Group, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.PubMedCrossRefGoogle Scholar
  10. 10.
    Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26(9):2518–23.CrossRefGoogle Scholar
  11. 11.
    Diabetes Prevention Program Research Group. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22(4):623–34.CrossRefGoogle Scholar
  12. 12.
    Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165–2171.CrossRefGoogle Scholar
  13. 13.
    Kriska AM, Knowler WC, LaPorte RE, et al. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. Diabetes Care. 1990;13(4):401–411.PubMedCrossRefGoogle Scholar
  14. 14.
    Pereira MA, FitzerGerald SJ, Gregg EW, et al. A collection of Physical Activity Questionnaires for health-related research. Med Sci Sports Exerc. 1997;29(6 Suppl):S1–S205.PubMedGoogle Scholar
  15. 15.
    Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med. 1994;11(3):286–292.PubMedCrossRefGoogle Scholar
  16. 16.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.PubMedCrossRefGoogle Scholar
  17. 17.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report on the Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183–1197.Google Scholar
  18. 18.
    Alberti K, Zimmet P, for the WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553.PubMedCrossRefGoogle Scholar
  19. 19.
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.PubMedCrossRefGoogle Scholar
  20. 20.
    McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40–66.PubMedCrossRefGoogle Scholar
  21. 21.
    Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–292.PubMedCrossRefGoogle Scholar
  22. 22.
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status.Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–415.PubMedCrossRefGoogle Scholar
  23. 23.
    Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003;1:4–11.PubMedCrossRefGoogle Scholar
  24. 24.
    Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43(7):736–749.PubMedCrossRefGoogle Scholar
  25. 25.
    Kontodimopoulos N, Pappa E, Papadopoulos AA, Tountas Y, Niakas D. Comparing SF-6D and EQ-5D utilities across groups differing in health status. Qual Life Res. 2009;18(1):87–97.PubMedCrossRefGoogle Scholar
  26. 26.
    Wyrwich KW, Tierney WM, Babu AN, Kroenke K, Wolinsky FD. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res. 2005;40:577–591.PubMedCrossRefGoogle Scholar
  27. 27.
    Ackermann RT, Edelstein SL, Narayan KM, Diabetes Prevention Program Research Group, et al. Changes in health state utilities with changes in body mass in the Diabetes Prevention Program. Obesity. 2009;17(12):2176–2181.PubMedCrossRefGoogle Scholar
  28. 28.
    Williamson DA, Rejeski J, Lang W, Van Dorsten B, Fabricatore AN, Toledo K, Look AHEAD Research Group. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med. 2009;169(2):163–171.PubMedCrossRefGoogle Scholar
  29. 29.
    Lynch CP, McTigue KM, Bost JE, Tinker LF, Vitolins M, Adams-Campbell L, Sarto GE, Hays-Grudo J, Manson JE, Kuller LH. Excess weight and physical health-related quality of life in postmenopausal women of diverse racial/ethnic backgrounds. J Womens Health. 2010;19:1449–1458.CrossRefGoogle Scholar
  30. 30.
    Vasiljevic N, Ralevic S, Marinkovic J, Kocev N, Maksimovic M, Milosevic GS, Tomic J. The assessment of health-related quality of life in relation to the body mass index value in the urban population of Belgrade. Health Qual Life Outcomes. 2008;6:106.PubMedCrossRefGoogle Scholar
  31. 31.
    Hahn S, Benson S, Elsenbruch S, Pleger K, Tan S, Mann K, Schedlowski M, van Halteren WB, Kimmig R, Janssen OE. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. Hum Reprod. 2006;21:1925–1934.PubMedCrossRefGoogle Scholar
  32. 32.
    Maciejewski ML, Patrick DL, Williamson DF. A structured review of randomized controlled trials of weight loss showed little improvement in health-related quality of life. J Clin Epidemiol. 2005;58(6):568–578.PubMedCrossRefGoogle Scholar
  33. 33.
    Daviglus ML, Liu K, Yan LL, Pirzada A, Garside DB, Schiffer L, Dyer AR, Greenland P, Stamler J. Body mass index in middle age and health-related quality of life in older age: the Chicago heart association detection project in industry study. Arch Intern Med. 2003;163(20):2448–2455.PubMedCrossRefGoogle Scholar
  34. 34.
    Cameron AJ, Magliano DJ, Dunstan DW, Zimmet PZ, Hesketh K, Peeters A, Shaw JE. A bi-directional relationship between obesity and health-related quality of life: evidence from the longitudinal AusDiab study. Int J Obes (Lond). 2012;36:295–303.CrossRefGoogle Scholar
  35. 35.
    Marrett E, Stargardt T, Mavros P, Alexander CM. Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes Obes Metab. 2009;11(12):1138–1144.PubMedCrossRefGoogle Scholar
  36. 36.
    Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ. 2005;14(11):1169–1189.PubMedCrossRefGoogle Scholar
  37. 37.
    Engel SG, Crosby RD, Kolotkin RL, Hartley GG, Williams GR, Wonderlich SA, Mitchell JE. Impact of weight loss and regain on quality of life: mirror image or differential effect? Obes Res. 2003;11(10):1207–1213.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2012

Authors and Affiliations

  • Hermes Florez
    • 1
    • 8
    • 9
    Email author
  • Qing Pan
    • 2
  • Ronald T. Ackermann
    • 3
  • David G. Marrero
    • 3
  • Elizabeth Barrett-Connor
    • 4
  • Linda Delahanty
    • 5
  • Andrea Kriska
    • 6
  • Christopher D. Saudek
    • 7
  • Ronald B. Goldberg
    • 1
  • Richard R. Rubin
    • 7
  • for the Diabetes Prevention Program Research Group
  1. 1.University of MiamiCoral GablesUSA
  2. 2.George Washington UniversityWashingtonUSA
  3. 3.Indiana UniversityBloomingtonUSA
  4. 4.University of CaliforniaOaklandUSA
  5. 5.Massachusetts General HospitalBostonUSA
  6. 6.University of PittsburghPittsburghUSA
  7. 7.Johns Hopkins UniversityBaltimoreUSA
  8. 8.Miami VAHS Geriatrics Research Education and Clinical CenterMiamiUSA
  9. 9.c/o Diabetes Prevention Program Coordinating CenterThe George Washington University Biostatistics CenterRockvilleUSA

Personalised recommendations